NAD+ and Exercise in FA (ExRx in FA)

Sponsor: Children's Hospital of Philadelphia
Collaborator: National Institutes of Health (NIH)

Purpose

The primary objective is to measure the effect of combination administration of NR and exercise on aerobic capacity in Friedreich's Ataxia. A key secondary objective is to measure the effect of combination administration of NR and exercise on glucose homeostasis in Freidreich's Ataxia.

Study Design

Randomized, placebo-controlled trial with a 2x2 factorial design, double blind

Dose

  • Individuals >72kg (158 lbs) will receive 900mg one time a day orally

  • Individuals >48kg (105 lbs) and ≤72kg (158 lbs) will receive 600mg one time daily orally

  • Individuals with weights 24 kg (52 lbs) ≤48kg (105 lbs) will receive 300mg one time daily orally

  • All dose levels will be matched by placebo

  • Doses with exercise of 3 aerobic sessions and 2 resistance sessions per week and placebo match

Length of Intervention

12 weeks

Intrinsic Capacity

Locomotion

Status

Recruiting

Condition or Disease 

Friedreich Ataxia 1

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Locomotion, RecruitingANAD Staff